GSK plc (LSE/NYSE: GSK) today announced a major new research collaboration with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to advance understanding of neurodegeneration with a first-of-its-kind dementia study

GSK plc（伦敦证券交易所/纽约证券交易所代码：GSK）今天宣布与英国痴呆症研究所（UK DRI）和英国健康数据研究所（HDR UK）达成一项重要的新研究合作，以推进对神经退行性病变的理解，并开展一项前所未有的痴呆症研究。

The innovative project aims to use the UK’s health data ecosystem to explore a potential association between GSK’s shingles vaccine, Recombinant Zoster Vaccine (RZV), and a reduced risk of dementia. If successful, this could serve as a blueprint for population level health data research models, reinforcing the UK’s position as a leading destination for scientific research..

该项目的创新之处在于，旨在利用英国的健康数据生态系统，探索葛兰素史克的带状疱疹疫苗——重组带状疱疹疫苗 (RZV) 与降低痴呆症风险之间潜在的关联。如果能够取得成功，这将成为人口层面健康数据研究模式的蓝图，进一步巩固英国作为科学研究中心的领先地位。

More than 55 million people worldwide have dementia

全球有超过5500万人患有痴呆症

, with cases increasing as the global population ages. Research to identify potential opportunities to reduce the risk of dementia is much needed but challenging given the multiple, complex factors which may contribute to the development of the disease

，随着全球人口老龄化，病例不断增加。鉴于可能导致这种疾病发展的多重复杂因素，识别降低痴呆风险的潜在机会的研究是非常必要但具有挑战性的。

Data from several retrospective observational studies show potential association between shingles vaccination, including with RZV, and a reduced risk of dementia

几项回顾性观察研究的数据表明，接种带状疱疹疫苗（包括RZV）可能与降低痴呆风险有关。

. However, the retrospective and observational nature of these studies means they are susceptible to unmeasured confounding factors and determining causal association has not been possible.

然而，这些研究的回顾性和观察性意味着它们容易受到未测量的混杂因素的影响，确定因果关系一直不太可能。

The new research collaboration aims to overcome this by using high quality, deidentified, population-level electronic health data from the UK’s National Health Service (NHS) to assess the impact of RZV vaccination on dementia risk reduction. There are around 1.4 million 65 and 66 years olds in the UK.

新的研究合作旨在通过使用来自英国国家医疗服务体系 (NHS) 的高质量、去标识化、人口级别的电子健康数据，来评估RZV疫苗接种对降低痴呆风险的影响，以此克服这一问题。英国有大约140万65岁和66岁的人口。

and their eligible electronic health records are expected to give a robust and comprehensive dataset which will account for factors such as RZV vaccination, age, sex and co-existing medical conditions. The research will take 4 years to complete.

预计他们符合条件的电子健康记录将提供一个强大而全面的数据集，该数据集将考虑 RZV 疫苗接种、年龄、性别和共存医疗条件等因素。这项研究将需要 4 年才能完成。

Tony Wood, Chief Scientific Officer, GSK, said:

葛兰素史克首席科学官托尼·伍德表示：

“GSK has a long-standing commitment to advancing science that tackles the most challenging health issues. The UK’s national scale health data resources provide a significant opportunity for cutting-edge research. We hope this world-class research collaboration will not only answer key questions to help reduce dementia risk but also pave the way for future data-led research to unravel the underlying causes of complex diseases so we can get ahead of them.”.

“GSK长期以来一直致力于推进应对最具挑战性健康问题的科学研究。英国全国规模的健康数据资源为前沿研究提供了重要机会。我们希望这一世界级的研究合作不仅能回答降低痴呆风险的关键问题，还能为未来数据驱动的研究铺平道路，以揭示复杂疾病的潜在原因，从而让我们占得先机。”

Science Secretary Peter Kyle said:

科学部长彼得·凯尔说：

“Dementia is one of the biggest challenges to health in our time, touching so many lives – which is why research to combat its devastating effects is so important. This is a wonderful example of the private sector working hand-in-hand with the public and third sector, leveraging the power of health data, to drive a greater understanding of how we might reduce the risk of dementia.”.

“痴呆症是我们这个时代对健康的最大挑战之一，影响着如此多的生命——这就是为什么研究对抗其毁灭性影响如此重要。这是一个私营部门与公共和第三部门携手合作，利用健康数据的力量，推动我们如何降低痴呆风险的更好理解的绝佳例子。”

Professor Andrew Morris, Director of Health Data Research UK, said:

英国健康数据研究中心主任安德鲁·莫里斯教授表示：

“Dementia represents one of the greatest challenges of our time, affecting millions of families across the UK and beyond. By working closely with the NHS in the four UK nations to ensure data privacy and security, we can enable prevention-focused research, deepen our understanding of disease and support the NHS in shifting from treating sickness to keeping people healthier for longer – helping them live better lives.”.

“痴呆症是我们这个时代最严峻的挑战之一，影响着英国及世界各地数百万家庭。通过与英国四个国家的国民保健署（NHS）紧密合作，确保数据隐私和安全，我们可以推动以预防为重点的研究，加深对疾病的了解，并支持国民保健署从治疗疾病转向帮助人们更长久地保持健康——帮助他们过上更好的生活。”

Professor Siddharthan Chandran, Director of UK Dementia Research Institute, said:

英国痴呆症研究所主任西达坦·钱德兰教授表示：

“Through cross-disciplinary collaboration that combines cutting-edge research capabilities with data at scale, we hope to showcase the potential of UK health data to improve not only our fundamental understanding of dementia but to identify potential interventions that could have a transformational impact.”.

“通过跨学科合作，将前沿研究能力与大规模数据相结合，我们希望展示英国健康数据的潜力，不仅能够加深我们对痴呆症的基本理解，还能够确定可能产生变革性影响的潜在干预措施。”

About EPI-ZOSTER-110

关于EPI-ZOSTER-110

EPI-ZOSTER-110 is a quasi-experimental, real world evidence analysis of adults aged 65 and 66 years at the time of the expansion of the UK Shingles National Immunisation Programme (NIP) on 1 September 2023

EPI-ZOSTER-110 是一项准实验性的现实世界证据分析，针对2023年9月1日英国带状疱疹国家免疫计划（NIP）扩展时年满65岁和66岁的成年人。

From that date, adults turning 65 years old became eligible to receive GSK’s Recombinant Zoster Vaccine (RZV). As part of a phased implementation plan, adults aged 66 years at the point of the expansion will become eligible for vaccination when they turn 70. This has created a natural randomisation, allowing for a comprehensive comparison of dementia risk by RZV vaccination status, while accounting for factors such as age, sex and other medical conditions which are expected to be broadly similar at a national level in this population..

从该日期起，年满65岁的成年人有资格接种GSK的重组带状疱疹疫苗（RZV）。作为分阶段实施计划的一部分，在扩大范围时年满66岁的成年人将在他们年满70岁时符合接种条件。这一安排形成了一种自然的随机化，允许在考虑年龄、性别和其他医疗状况等因素的情况下，全面比较接种RZV疫苗与未接种者之间的痴呆风险，而这些因素在这一人群的国家层面上预计大致相似。

The data will be collected from deidentified electronic health records (EHR) comprising information from multiple linked health datasets, including primary care, secondary care, medication records, and death records, from England, Scotland, Wales, and Northern Ireland. These data provide information on health outcomes across all age groups, ethnicities, geographic locations, socioeconomic and personal characteristics.

数据将从去标识化的电子健康记录（EHR）中收集，这些记录包含来自英格兰、苏格兰、威尔士和北爱尔兰的多个关联健康数据集的信息，包括初级保健、二级保健、药物记录和死亡记录。这些数据提供了涵盖所有年龄组、种族、地理位置、社会经济和个人特征的健康结果信息。

Following a feasibility assessment, EHRs will be securely analysed for around four years until the 66-year-olds turn 70 and become eligible for RZV..

在可行性评估之后，电子健康记录将在约四年内被安全分析，直到66岁的人年满70岁并符合接种RZV的资格。

Deidentified health data are held by National Health Services and may only be accessed via trusted and secure research environments complying with data privacy and security regulations. The study data will not be owned by GSK, nor accessible for purposes outside the scope of this study.

去标识化的健康数据由国家卫生服务部门持有，只能通过符合数据隐私和安全法规的可信且安全的研究环境访问。研究数据将不由GSK拥有，也不可用于本研究范围之外的目的。

Usage of RZV in this study population will be in accordance with the UK product label and NIP.

本研究人群中的RZV使用将符合适应英国的产品标签和NIP。

About Recombinant Zoster Vaccine

关于重组带状疱疹疫苗

Recombinant Zoster Vaccine (or RZV) is a non-live, recombinant subunit vaccine indicated for the prevention of shingles in adults aged 50 years and over. It combines an antigen, glycoprotein E, with an adjuvant system, AS01B, and may help overcome the natural age-related decline in responses to immunisation that contributes to the challenge of protecting adults aged 50 and over from shingles.

重组带状疱疹疫苗（RZV）是一种非活的重组亚单位疫苗，适用于预防50岁及以上成人带状疱疹。它结合了一种抗原——糖蛋白E，以及一种佐剂系统AS01B，可能有助于克服因年龄增长导致的免疫应答自然下降，从而应对保护50岁及以上成人免受带状疱疹困扰的挑战。

. RZV is not indicated to prevent primary varicella infection (chickenpox). In several countries, RZV is also approved for adults aged 18 years or over at increased risk for shingles. The use of RZV should be in accordance with official recommendations and local product label.

RZV不用于预防原发性水痘感染（水痘）。在一些国家，RZV也被批准用于18岁及以上带状疱疹风险增加的成人。RZV的使用应遵循官方建议和当地产品标签。

About GSK

关于GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

GSK是一家全球生物制药公司，致力于联合科学、技术和人才，共同战胜疾病。欲了解更多信息，请访问gsk.com。

About Health Data Research UK

关于健康数据研究所英国

Health Data Research UK is the national institute for health data science – accelerating trustworthy use of health data to enable discoveries that improve people’s lives. It is a charity funded by UK Research and Innovation, the Department of Health and Social Care in England and equivalents in Northern Ireland, Wales and Scotland, and leading medical research charities.

健康数据研究所（Health Data Research UK）是英国的国家健康数据科学研究所，致力于加速健康数据的可信使用，推动改善人们生活的发现。该机构是一家慈善组织，由英国研究与创新署、英格兰卫生和社会关怀部以及北爱尔兰、威尔士和苏格兰的相关部门和领先的医学研究慈善机构资助。

About UK Dementia Research Institute

关于英国痴呆症研究所

The UK Dementia Research Institute (UK DRI) is a globally leading multidisciplinary research institute principally funded by the Medical Research Council. The UK DRI is dedicated to changing the outcomes of people living with or at risk of neurodegenerative conditions, by accelerating the discovery, development and delivery of interventions that will help diagnose, treat, and ultimately prevent dementia.  www.ukdri.ac.uk.

英国痴呆症研究所（UK DRI）是一个全球领先的多学科研究机构，主要由医学研究委员会资助。英国痴呆症研究所致力于通过加速发现、开发和交付有助于诊断、治疗并最终预防痴呆症的干预措施，来改变生活或面临神经退行性疾病风险人群的结果。www.ukdri.ac.uk。